Form 4: Investors Title Co Director Tammy Coley Acquires Stock Appreciation Rights
SEC Form 4
Director Tammy Coley acquired 750 Stock Appreciation Rights (SARs) of Investors Title Co on May 21, 2025.
Summary
- On May 21, 2025, Tammy Coley, a director of Investors Title Co, acquired 750 Stock Appreciation Rights (SARs) at a price of $246.75.
- These SARs are exercisable starting June 30, 2025, and expire on May 21, 2032.
- The transaction was reported on May 22, 2025.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it simply reports a transaction. The acquisition of SARs by a director could be seen as a slightly positive sign, but without further context, it's difficult to assess the overall impact.
Positives
- A director's acquisition of SARs could be interpreted as a positive signal, indicating confidence in the company's future performance.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.
Stakeholder Impact
- The acquisition of SARs by a director may have a minor positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 05/21/2025 | Date of transaction: Acquisition of Stock Appreciation Rights |
| 05/21/2025 | Date of transaction: Stock Appreciation Right Price $246.75 |
| 05/22/2025 | Date of Form 4 filing |
| 06/30/2025 | Date Stock Appreciation Rights become exercisable |
| 05/21/2032 | Expiration date of Stock Appreciation Rights |
Keywords
Stock Appreciation Rights, SARs, Director, Beneficial Ownership, Form 4, ITIC, Investors Title Co, Acquisition
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.